ILLUMINATE-B Phase 3 Results for OXLUMO® (lumasiran) Published in Pediatric Nephrology

ILLUMINATE-B Phase 3 Results for OXLUMO® (lumasiran) Published in Pediatric Nephrology

Results from the 12-month analysis of the ongoing ILLUMINATE-B Phase 3 open-label pediatric study of OXLUMO® (lumasiran) in patients less than six years of age with primary hyperoxaluria type 1 (PH1) were published online in Pediatric Nephrology.

Read the paper in the Pediatric Nephrology